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Biopharmaceutical innovation has had a profound health and economic impact globally. Developed countries have
traditionally been the source of most innovations as well as the destination for the resulting economic and health
benefits. As a result, most prior research on this sector has focused on developed countries. This paper seeks to fill
the gap in research on emerging markets by analyzing factors that influence innovative activity in the indigenous
biopharmaceutical sectors of China, India, Brazil, and South Africa. Using qualitative research methodologies, this
paper a) shows how biopharmaceutical innovation is taking place within the entrepreneurial sectors of these
emerging markets, b) identifies common challenges that indigenous entrepreneurs face, c) highlights the key role
played by the state, and d) reveals that the transition to innovation by companies in the emerging markets is
characterized by increased global integration. It suggests that biopharmaceutical innovators in emerging markets
are capitalizing on opportunities to participate in the drug development value chain and thus developing
capabilities and relationships for competing globally both with and against established companies headquartered
in developed countries.
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The UNESCO Science Report 2010 shows that the
emerging markets of China, India and Brazil are, by
many indications, leading most of the world in the pace
of scientific and technological development. The grow-
ing research and development (R&D) expenditures and
rising global share of scientific publications and patent-
ing rates in these countries (see Table 1) reflect efforts
by diverse actors to compete globally. National policies,
domestic economic growth, and global trends over the
last several decades have stimulated growth and
innovation within domestic biopharmaceutical enter-
prises in China, India, Brazil and South Africa (which
hereafter we call ‘emerging markets/economies’). In-
creasingly, this growth and innovation has led to unique* Correspondence: peter.singer@srcglobal.org
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reproduction in any medium, provided the oradvantages that allow some emerging-market firms to
compete effectively on global markets rather than to
serve primarily as suppliers, vendors and outsourcers to
developed-country pharmaceutical multinational cor-
porations. Growth in the pharmaceutical sectors of these
four emerging countries continues to outpace that in
developed countries (see Table 1). Brazilian and South
African policy objectives have thus far focused primarily
on import substitution and lowering the cost of health
products for local populations. In contrast, those of
India and China aim at nurturing an innovation ecosys-
tem and a vibrant bio-economy with greater ambitions
for exportation from the sector.
While earlier research has focused on technology
transfer through foreign direct investment, alliances,
and other cross-border partnerships to boost develop-
ing-country entrepreneurship [1], indigenous innova-
tion and entrepreneurship are receiving increasing
attention as means of improving the health and wealth
of the poor directly and for cultivating knowledgeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Key R&D, publication, patenting, and pharmaceutical market indicators for China, India, Brazil, South Africa
and select developed markets
Country R&D Expenditure



















China 1.5 (2008) 102 12%, [23.4%] 26.5% 25.7 (48.8) 17.3% (13.6%)
India 0.80 24.8 2.3%, [4.7%]** 42%* 14.1 (30.4) 16.6% (16.6%)
Brazil 1.10 20.3 1.6%, [12.2%]*** N/A 15.3 (34.4) 13.1% (17.6%)
Canada 1.84 (2008) 24.0 2.7% 3.9% 26.6 (30.2) 5.4% (2.6%)
Germany 2.54 72.2 4%08 5.7% 37.9 (41.5) 3.4% (1.8%)
Japan 3.44 148 4.8% 4.5% 72.4 (102.7) 4.4% (7.2%) ****
United States 2.82 (2008) 398 16% 2.6% 292.8 (344.7) 2.9% (3.3%)
Sources: 1 UNESCO Science Report 2010. Data is for 2007 unless stated otherwise.
2 OECD Science, Technology and Industry Outlook 2010. Share of publications is for 2008, except for India where this share represents 2006 Data.
3 DataMonitor 2010, Country-specific Pharmaceutical Industry Profile Reports.
* Estimate for India is for period 1997–2004.
** Estimate for India is for 1995–2005.
*** Estimate for Brazil is for 1998–2008.
**** Data for 2005–2009 and 2009–1014.
CAGR stands for Cumulative Annual Growth Rate.
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search shows that the global pharmaceutical multi-
national corporations (MNCs) based in resource-rich
countries have tended not to develop drugs for exclu-
sive use in the developing world or to make significant
investments in drug development for neglected dis-
eases [3-5]. The role of emerging market firms in fill-
ing this gap, as well as enhancing affordability, is of
much interest, but is not a key focus for this paper.
Suffice it to say that previous publications [6], and our
ongoing studies, do suggest that emerging market
firms, as a group, have a greater overall focus on
addressing developing-world diseases than their major
global competitors. Nonetheless, we have also argued
[7] that diseases that almost exclusively affect poor
market segments in the developing world are unlikely
to be addressed by emerging market firms as well, and
require specific attention from the global health com-
munity and local and international governments.
This paper analyzes key issues and implications of cor-
porate innovation in emerging economies. The core re-
search questions we address here are: how do health
technologies develop in emerging economies? Have
companies in emerging economies specialized on tech-
nologies? What entrepreneurial strategies and enterprise
structures have been commonly used to facilitate
the transition into business models that emphasize
innovation? What are the key barriers to health product
innovation? What is the role of the state in innovation
within health enterprises in the emerging markets? What
is the role of emerging market companies in the global
pharmaceutical sector, and how do emerging-market
competitors interact with incumbent firms based in the
developed economies?The results of our analysis of the mechanisms that
shaped corporate competitiveness in emerging markets
yields insights at two levels: first, on country policies
that enable and support technological upgrading and
specialization; and second, on entrepreneurial strategies
and business models that enhance corporate innovation
and global competitiveness.
Methods
The basis of this article is qualitative case study analysis
of indigenous biopharmaceutical enterprises in each of
Brazil, China, India and South Africa. Qualitative re-
search approach was chosen as it can help us understand
a phenomenon of interest in its complexity, to identify
areas that need to be influenced, and to see the conse-
quences of policy intervention in real life ([8]; p.10). This
analysis builds on a series of country-specific studies
published in the Nature Biotechnology journal [9-12],
which focused on products and services, partnerships,
intellectual property (IP) portfolios, business models, fi-
nancial environments and barriers to development for
companies in each country. This analysis is a compara-
tive assessment across the four nations and is informed
by face-to-face interviews with representatives of 91 do-
mestic biopharmaceutical companies (Table 2) as well as
25 other institutions in the stated countries. Institutional
informants included government agencies involved in
biopharmaceutical development, venture capital firms,
technology parks/incubators, and industry associations.
The interview data complemented insights gained from
published reports and articles, websites of companies
and relevant government institutions and policy docu-
ments. Interview data was employed to enhance confir-
mation of and elaboration upon documentary evidence.
Table 2 Health biotech firms from China, India, Brazil and South Africa included for this analysis
China India Brazil South Africa






Beijing Haiyan Pharmaceutical Advinus Therapeutics BioCancer Altis Biologics
Beijing Wantai Biological Pharmacy Enterprise Bharat Biotech International Biolab Sanus Farmacêutica AngioDesign
Bio-Bridge Science Bhat Bio-Tech India BioGene Arvir Technologies
CapitalBio Corporation Bharat Serums andVaccines BIOMM Technology Aspen Pharmacare
FusoGen Pharmaceuticals BigTec Laboratories COINFAR Bioclones
GeneScience Pharmaceuticals Biocon Cryopraxis Criobiologia Biomox
Hutchison MediPharma Biological E Eurofarma Laboratórios Biovac Institute
HD Biosciences Dr. Reddy’s Laboratories FK Biotecnologia Cape Kingdom
Kanghong Pharmaceutical Group GangaGen Biotechnologies Hebron Farmacêutica Disa Vascular
Shanghai Ambrosia Pharmaceutical Indian Immunologicals Intrials Clinical Research Elevation Biotech
Shanghai Fudan-Yueda Bio-Tech Jubilant BioSys Katal Biotecnológica Gknowmix
Shanghai Genomics LifeCare Innovations Labtest Diagnóstica Kapa Biotech
Shanghai Genon Bio-Engineering Lupin Pharma Nortec Química National Bioproducts
Institute
Shanghai Huaguan Biochip Piramal Life Sciences Pele Nova Biotecnologia Synexa Life Sciences
Shanghai Sunway Biotech. Panacea Biotec Recepta Biopharma Veritrial Clinical Trials
Shanghai United Cell Biotech Reliance Life Sciences Scylla Bioinformatics Vision Biotech
Shenzhen Beike Biotechnologies Serum Institute of India Silvestre Laboratories
Shenzhen Chipscreen Biosciences. Shantha Biotechnics União Química
Shenzhen Tiandakang Gene Engineering Strand Life Sciences
SiBiono GeneTech Suven Life Sciences
Simcere Pharmaceutical Group Transgene Biotek
SinoCells Biotech Wockhardt
SinoGenoMax Clinigene




Zensun (Shanghai) Sci. &Tech. Co., Ltd.
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opment and production of vaccines, therapeutics, and
diagnostics. With a few exceptions, interview data was
collected through site visits and semi-structured, face-
to-face interviews lasting approximately 60–90 minutes.
Results and discussion
Health technology innovation and the emerging markets
The modern pharmaceutical industry finds its origins in
the synthetic dye industry in Germany and Switzerland
and the discovery of medicinal effects of some dyestuffs
[13]. The large-scale production of penicillin during
World War II spawned considerable R&D investments
and productivity in terms of pharmaceutical innovations
particularly by the major US-based companies [13]. The
1976 inception of Genentech (San Francisco, now part
of Roche based in Basel, Switzerland) spawned themodern biotechnology industry. The latter is character-
ized by many small- and medium-sized enterprises
(SMEs). With the exception of a few large firms, biotech
SMEs are dispersed across a considerable number of
countries. Notwithstanding somewhat distinct develop-
mental trajectories, pharmaceutical and health biotech-
nology sectors are increasingly intertwined due to
mergers and acquisitions and overlapping activities.
While key firms remain based in a relatively small group
of countries – including the U.S., the United Kingdom,
Switzerland, Germany, and France – the global disper-
sion of their activities is increasing, as is the emergence
of indigenous firms in different countries.
The geographic concentration of innovative activities
in health technology is thought to be a function of his-
torical differences in institutional environments [13].
Therefore, it is of interest to examine how the changing
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impacted the development of biopharmaceutical sectors
in these nations. The adoption of the World Trade
Organization’s Trade-related Aspects of Intellectual
Property Rights (TRIPS) agreement has been among key
institutional adjustments and has enhanced the impetus
to innovate. It is against this backdrop that we witness a
growing number of firms in the emerging markets build-
ing innovative capability. This capacity may be particu-
larly crucial in the post-TRIPS era where the power of
emerging market manufacturers to affect drug prices in
poor markets is likely to be diminished [14], and drug
prices rise due to the marketing of high priced products
by pharmaceutical MNCs [15].
Innovation, technological upgrading and industry
specialization
The health biotech sectors of emerging economies are
undergoing a major transformation characterized by
increased technological sophistication of product portfo-
lios and R&D activities. In a recent study, we identified
376 medicinal or vaccine candidates within the pipelines
of 66 indigenous companies in China, India and Brazil
(Unpublished Results). An estimated 60% of the 376
candidates involve new chemical or molecular entities,
and as such could be considered new-to-the-world type
of innovations. The rest include innovations that build
on known molecules or products. Among the 376 candi-
dates identified, over two-thirds are in the discovery or
preclinical stage, and only about 3% (11) of products
have reached the domestic market. These results, to-
gether with studies cited previously, demonstrate that
domestic companies in the emerging markets are devel-
oping new capabilities and novel health products, but
also that they are at a relatively early stage from the per-
spective of innovation.
A common strategy for entrepreneurs in emerging
economies has been to develop technologically and fi-
nancially less demanding products before venturing into
more sophisticated areas as internal capabilities and rev-
enues improve. Historically the major thrust of firms in
emerging economies has been mainly to offer non-novel
products and services under contract to established
pharmaceutical multinational firms, or as low-technol-
ogy traditional formulations. By and large, the develop-
ment of globally innovative products by emerging
market firms is a relatively recent phenomenon and has
been enabled by a number of factors. Reverse engineer-
ing of existing drugs has had a considerable learning ef-
fect for industries in China, India and Brazil, facilitating
the adoption of new technologies and easing the transi-
tion into innovative activities. Firms have not only
gained experience in health product manufacturing and
marketing, but have also developed the necessarytechnical expertise to allow them to venture into more
sophisticated areas. In this respect, the absence of a
strong domestic pharmaceutical manufacturing sector in
South Africa puts it in a different category than the
other three countries studied, resulting in the dearth of a
skilled knowledge base on which to build.
A key driver of technological upgrading, particularly
by Indian firms, has been an interest in export markets,
including the major markets of the U.S. and Europe.
While domestic populations constitute the main market
– at least presently – for most health biotech enterprises
studied, there is a growing interest among executives in
many medium and large firms to export products. Thus
far, export of finished products is notable only in India,
where the traditional pharmaceutical sector has
increased its foreign sales by over 21% annually between
1996 and 2005 [16] and the country’s fast-growing bio-
tech sector, as a whole, garners 56% of its revenues from
exports [17]. Major Indian firms have been able to in-
crease exports to the U.S. and elsewhere, by upgrading
their manufacturing facilities to meet the U.S. Food and
Drug Administration (FDA) requirements. The growing
number of strategic alliances between pharmaceutical
MNCs and Indian companies also allows the latter
group of firms to capitalize on their manufacturing cap-
acity and the considerable marketing resources of MNCs
to address global markets [15]. In contrast, few compan-
ies in China, Brazil, and South Africa have thus far
exported finished medicines to highly regulated markets.
This trend is likely to change however, as these countries
continue to enhance their own manufacturing standards.
Notwithstanding the fact that health biotech industries
in the emerging markets are in a transition period, one
can observe patters of specialization by country. Diag-
nostics and medical devices were common starting
points for a number of firms in Brazil and South Africa,
respectively, while vaccines represent a major entry
point for many firms in India. For instance, Hyderabad-
based firms Bharat Biotech and Shantha Biotechnics
(now part of Paris-based Sanofi-Aventis) started out in
vaccine manufacturing, and have since expanded their
range of activities to include manufacturing of other re-
combinant products. China’s Beijing Wantai, primarily a
diagnostics company, has focused on innovative research
including efforts to commercialize a novel hepatitis E
vaccine. Similarly, Brazil’s FK Biotech (Porto Alegre) has
expanded its range of activities from manufacturing of
monoclonal antibodies for diagnostic kits to develop-
ment of cancer vaccines. Starting with local markets,
some firms have become major players at a global scale.
Vision Biotech (Cape Town, South Africa) for example
claimed to be the second-largest manufacturer of rapid
tests for malaria worldwide, and the Serum Institute of
India (Pune) is a major global vaccine supplier. Also, a
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ies are developing manufacturing capabilities for recom-
binant products, with many in India and China already
benefiting from related efforts over the past decade.
Indian companies have become key global vaccine
suppliers. A dozen vaccine companies generate over 50%
of the annual revenues for the biotech sector, a market
that reached US$2.5 billion in 2007/8 [17]. The entry of
Indian, as well as some other developing-country firms,
into vaccine production took off in the 1990s as manu-
facturers in the industrialized countries began to aban-
don these markets in favor of more lucrative ones
elsewhere [18]. It has been suggested that the emergence
of Global Alliance for Vaccines and Immunization
(GAVI) and the GAVI Fund played a significant role in
stimulating the technological expansion of developing
world vaccine manufacturers particularly in India and
Brazil [18]. Among the largest Indian vaccine producers
are Serum Institute of India, Panacea Biotec (New
Delhi), Biological E (Hyderabad), Bharat Biotech and
Shantha Biotechnics. Some of these firms have become
major global suppliers of vaccines to public immu-
nization programs in collaboration with the UNICEF,
PAHO and the WHO [11]. Recent involvement of Indian
companies - namely, Bharat Biotech, Zydus Cadila
(Hyderabad), Panacea Biotech, the Serum Institute and
Biological E - in the race towards a domestically devel-
oped vaccine for H1N1 influenza signals the country’s
growing technological capability in vaccine development.
It is worth mentioning that some of these firms relied
on in-licensing of the core technology from foreign
firms. Other key focus areas for the Indian firms include
a growing trend towards production of biogenerics and
the discovery and development of novel small-molecule
drug candidates. Mumbai-based Piramal Life Sciences
and Glenmark Pharmaceuticals are among the leaders in
this group, each having over 10 lead drug candidates in
development. Other Indian firms are working on devel-
oping new drug delivery systems, monoclonal antibodies
and diagnostic tests, and manufacturing recombinant
medicines [11]. In anticipation of India’s adoption of the
TRIPS agreement in 2005, the pharmaceutical industry
in India spent approximately US$292 million (13.2 bil-
lion Indian rupees) on R&D between 2003–2004,
accounting for 3.6% of overall revenues [19]. The global
competitiveness of India’s private industry in both vac-
cines and therapeutics is, in part, a result of the relative
openness of its domestic market and limited involve-
ment of the government sector in health product manu-
facturing. In China and Brazil (and until recently in
South Africa), the prominent role of state-sponsored or
public sector institutes in vaccine development and pro-
duction has diminished the scope for the domestic pri-
vate sector in this area.Chinese firms involved in innovation have a consider-
able focus on developing novel therapeutics in frontier
areas and often leverage traditional Chinese medicine
(TCM) knowledge and resources. Gene therapies against
some cancers, developed by Shenzhen SiBiono (Shenzhen)
and Shanghai Sunway (Shanghai), have been on the mar-
ket for over four years [10]. As of mid-2009, approxi-
mately 9,000 patients had been treated for head and neck
cancer with SiBiono’s innovative gene therapy product,
marketed as GendicineW, approximately 1,200 of whom
came from outside China. Other innovative projects in the
pipeline included a novel drug candidate for cutaneous T-
Cell lymphoma by Shenzhen Chipscreen (Shenzhen), an
HIV treatment candidate by Fusogen (Tianjin) and pro-
ducts to address lung fibrosis and liver cirrhosis by Shang-
hai Genomics. There are also significant efforts towards
modernization of TCM, involving manufacturing quality
control, efficacy tests, and determining active ingredients
and their mechanisms of action. While China’s efforts to-
wards new vaccine development have generally trailed be-
hind India, strong emphasis by the Chinese government
in recent years on technological advancement in this area
may be reversing this trend. The Chinese vaccine-
manufacturing sector is one of the largest in the world in
terms of production volume, where approximately 30 vac-
cine manufacturers, mostly domestic enterprises, produce
over a billion vaccine doses annually [20]. As a sign of re-
cent progress, Sinovac Biotech (Beijing) gained manufac-
turing approval in September 2009 from the Chinese State
Food and Drug Administration (SFDA) for its single-dose
H1N1 vaccine – a time frame similar to leading global
firms and preceding the launch of clinical trials by its In-
dian counterparts mentioned above.
The Brazilian health biotech industry is populated by a
growing number of technology-based small and medium
sized (SME) enterprises as well as generics-based
pharmaceutical incumbents, some of whom are transi-
tioning to innovative R&D activities. Overall, the sector
remains very young with the vast majority of health bio-
tech enterprises coming into existence in the past de-
cade [21]. A handful of the SMEs we studied had
marketed and/or were developing novel technologies.
Examples of these firms include Pele Nova Biotechnolo-
gia, Recepta Biopharma (both in São Paulo), and FK Bio-
tec (Porto Alegre). Some of these firms have leveraged
early success in diagnostics to develop more techno-
logically advanced products [9]. Similarly, large generics
firms including Cristália (Itapira) and Aché Laboratories
(São Paulo) are building capabilities in discovery and de-
velopment of innovative drugs. Some firms such as Aché
and Eurofarma (São Paulo) were developing capabilities
to manufacture large molecules, as part of their foray
into biotechnology. However, regardless of size, Brazilian
companies tend to shy away from vaccine development
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country’s public sector in this area. Furthermore, in
Brazil and China the public sector supplies a consider-
able portion of basic medicines deemed essential for
public health. Where public and private domains have
significant, overlapping, and unclear boundaries it can
create tension between the sectors [9], possibly detract-
ing from the country’s overall innovative capacity.
The nascent health biotech sector in South Africa relies
considerably on the research capabilities of the country’s
universities and research institutes to identify novel tech-
nologies and products for commercial development [12].
For example, Elevation Biotech (Johannesburg), which
was spun out of the University of Witwatersrand and the
National Health Laboratory Service (both in Johannes-
burg), is developing novel peptides to inhibit HIV entry
into cells. Elevation has received grants from the South
African government and the International AIDS Vaccine
Initiative (New York) to develop and test new vaccine
antigens. Other innovative firms include: iThemba Phar-
maceuticals (Modderfontein) focused on drug develop-
ment for tuberculosis (TB), malaria and HIV/AIDS, Arvir
Technologies (Modderfontein) is developing cost-effective
methods to manufacture HIV drugs, and Disa Vascular
(Cape Town), which is involved in development and
manufacturing of coronary artery stents. A few South
African firms have also ventured into nutraceuticals in-
cluding Biomox Pharmaceuticals (Pretoria) and Cape
Kingdom (Cape Town). Biovac Institute (Cape Town) was
founded in 2003 as a public-private partnership to supply
South Africa’s vaccination program, after attempts at a
purely public system failed to accomplish this goal. It
remains the only vaccine manufacturer in Sub-Saharan
Africa.
In all four countries, locally abundant natural re-
sources are increasingly leveraged to identify and de-
velop novel health technologies. Biodiversity resources
and traditional medicines serve as a major source for
lead compound identification for firms in the emerging
markets. For example, Shanghai Ambrosia Pharmaceuti-
cals (Shanghai) uses its novel platform technologies to
screen TCMs for lead molecules against cancer and im-
munological diseases. Brazil’s Aché Pharmaceuticals and
Pele Nova Biotechnologia have marketed phytotherapeu-
tic-based products used for inflammation and skin
lesions respectively, and a number of others are develop-
ing other products originating from Brazilian biodiver-
sity [9]. India’s Piramal Life Sciences, in collaboration
with public universities and research institutes, has
developed a large bank of natural products and product
extracts as well as a microbial library containing over
40,000 different cultures. Many of the company’s lead
molecules under study – including some in clinical trials
– were sourced from these assets. Avesthagen (Bangalore)uses a multi-disciplinary approach to develop health pro-
ducts, including dietary supplements, drawing extensively
on knowledge from Indian medicinal plants.
Specialization patterns are broadly reflective of a com-
plex interplay involving the institutional environment in
each country, local knowledge as embodied in univer-
sities and research institutes, access to unique and
country-specific resources, the divergent involvement of
the public sector in health product manufacturing and
provision, and the evolving competition and cooperation
between local and global rivals.
Entrepreneurial innovation strategies and business models
As recently as a decade ago, life-sciences firms in emer-
ging markets were engaged mainly in activities such as
manufacturing, formulating, packaging and distributing
generic products. By contrast, today a much broader
scope of business models and strategies are used to gen-
erate revenues and invest for future prosperity across
the emerging markets. A growing number of firms view
product R&D as an important component of their busi-
ness models. However, the extent of their commitment
to R&D and the nature of their involvement vary across
firms and countries. The divergent involvement in
innovation is influenced by two key factors. Global
MNCs have historically tended to concentrate in high
margin market segments in the emerging markets, leav-
ing domestic companies to settle for second and third
tier cities, rural areas and other neglected niche seg-
ments. The resulting pressure on margins for local com-
panies, together with dearth of private capital to support
biopharmaceutical innovation has meant that indigenous
firms have also had to innovate in business models.
First, the relatively few pure R&D firms in existence
today, such as Recepta BioPharma (Brazil), Fusogen
Pharmaceuticals Inc. (China), and iThemba Pharmaceu-
ticals (South Africa), have tended to garner significant
support from governmental sources. Most companies we
studied in China, Brazil and South Africa had received
some government funding for their innovation projects.
Indian firms have traditionally had less direct support
from government sources, perhaps contributing to the
near absence of a pure R&D-based business model
among firms in this country.
Second, health enterprises studied rely considerably on
partnerships with domestic universities and research
institutes as well as foreign entities. Firm-university lin-
kages typically serve to fill in gaps in internal R&D cap-
abilities and access facilities/equipment and, to a lesser
extent, to the transfer of new technologies to firms. Not-
withstanding these benefits domestic university-company
links remain weak overall, largely for cultural and histor-
ical reasons. There appears to be a strong correlation be-
tween the degree of firms’ engagement in innovative
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tic universities and research institutes in all countries
studied. For example, R&D-intensive firms such as
Recepta Biopharma of Brazil, Shanghai Sunway and Sino-
vac Biotech of China, and Avesthagen in India have
strong collaborations with academic institutions. Simi-
larly, most South African firms, which are often estab-
lished to commercialize technologies originating from
universities, maintain close linkages with these institutes.
In contrast, domestic entrepreneurial collaboration, par-
ticularly partnerships aimed at product development,
appears limited across all countries studied.
Third, most innovation-minded entrepreneurs have
adopted an indigenous growth model at or shortly after
inception, where R&D activities are financed through in-
ternal revenue generation. The result is that these enter-
prises often undertake two distinct sets of activities: one
set aims at generating revenues in the short-term, while
the other is focused on innovation for long-term growth.
For example, when Mr. Eduardo Cruz, the founding dir-
ector of Cryopraxis (Rio de Janeiro), wished to start a
company in 2000 that would develop stem-cell therapies,
his initial strategy was to start a cord blood banking ser-
vice to help finance R&D activities. A common approach
for generating revenues in all four countries remains the
in-house manufacturing and marketing of products, be
they generics, copycat therapeutics, or modifications of
existing health products often targeted at niche markets.
Another prevalent strategy among innovative firms in
China and India is to offer a variety of product develop-
ment and/or manufacturing services, often to foreign cli-
ents. Examples of firms that grew by utilizing this model
include India’s Bharat Biotech and the Chinese firms
Shenzhen Chipscreen and Shanghai Genomics. In indus-
trialized economies it is well established that financing
new product development with current revenues is more
expensive and constraining compared to investment-
driven financing. Nonetheless, even where available,
emerging market equity investors typically demand rev-
enues from early on in Investee Company’s life cycle –
in some cases causing them to abandon innovative pro-
jects with extended development periods.
Fourth, a relatively recent trend particularly notable in
China and India is growing international linkages of do-
mestic firms to advance innovative R&D activities. These
partnerships often manifest in one of two forms – out-
sourcing or co-development arrangements. The pro-
vision of contract R&D services in the emerging markets
is relatively new and transactional in that services are
rendered in return for payments upon completion of
specified milestones. Previously, domestic companies
only offered manufacturing and clinical research services
with limited capability in other aspects of drug discovery
and development. Companies adopting the newer modeltypically serve foreign clients by focusing on discovery
and development as well as contract manufacturing for
proprietary health products. Among a growing group of
service providers are China’s Wuxi Pharmatech, Sundia
Meditech Company (both in Shanghai) and India’s Advi-
nus Therapeutics (Bangalore) and Jubilant Organosys
(Noida), all of whom have enjoyed considerable growth
in recent years. Co-development projects on the other
hand involve joint discovery and/or development of
novel technologies between Indian and Chinese firms
and foreign counterparts, usually large multinational
corporations (MNCs). China’s Hutchison MediPharma
(Shanghai) is an integrated R&D company whose discov-
ery and development activities are supported, in part,
through relationships with Eli Lilly (Indianapolis, IN),
Merck KGaA (Whitehouse Station, NJ) and Johnson &
Johnson’s subsidiary Ortho-McNeil-Janssen Pharmaceu-
ticals (Raritan, NJ). India’s Jubilant Biosys (Bangalore)
and Suven Life Sciences (Hyderabad) are other examples
of companies that have significant levels of collabora-
tions with multinational firms. What distinguishes co-
development from outsourcing is that under the former
approach, the emerging-markets partner shares in
longer-term risks and returns form commercialization
projects. Such relationships are motivated, in part, by
the desire on the part of multinationals to reduce drug
development costs by tapping cheaper scientific labor in
the emerging markets. Benefits to domestic firms in-
clude: access to financing for innovative projects,
technological learning, sharing of future royalties, and
reputational advantages of working closely with major
global enterprises.
Barriers to innovation
Our analysis revealed a number of important barriers
that hinder entrepreneurial progress in health product
innovation in the countries studied. Although many of
the challenges are similar across the four countries stud-
ied, the underlying mechanisms that give rise to the
challenges differ.
Human resources
While all four countries have expanding capabilities in sci-
ence and technology in general and life sciences in particu-
lar, access to specially trained personnel in health biotech
innovation is often limited. The most common strategies
to fill shortage of skilled labor have been to: a) increase sci-
ence and technology capacity in general through invest-
ment in R&D, b) develop targeted training programs, and
c) recruit highly trained personnel from abroad. As a result
of the first strategy, all countries studied have increased
their relative contribution to global scientific publications
in recent years. In particular, China’s publication and cit-
ation rates have been rising substantially, making it the fifth
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lications grew at an average annual rate of 16.5% between
1995–2005, compared with 4.7 and 8% for India and Brazil
respectively [23]. While this trend speaks to a strengthen-
ing of the science and technology base, it is often not suffi-
cient to address shortages of specially trained personnel.
Efforts by the emerging economies to train personnel do-
mestically are not only time-consuming, but face chal-
lenges of their own. Many training programs relevant to
health biotech in the emerging economies are based in uni-
versity systems, which have been traditionally isolated from
industry. As a result they are not perceived to be effective
at detecting and addressing the changing industrial
demands.
Nonetheless, some efforts in this regard are underway.
For example, India’s Department of Biotechnology has a
number of programs including sponsorship of post-
graduate training in biotechnology and the provision of sti-
pends for post-graduate students to work in the industry
for six months. Similarly, Brazil has initiated a program that
sponsors researchers’ salaries for a period of time while they
work in the industry. South Africa’s human resource chal-
lenges seem related to the country’s inability to sufficiently
retain highly trained individuals [12] and the lack of a
strong pharmaceutical manufacturing sector to provide a
basic skill-set for further industrial development. Lastly, the
Chinese, and to a lesser extent Indian, industries have been
beneficiaries of returnees, who in many cases have obtained
specialized training abroad and have strong scientific and
commercial networks. China’s post-1978 policies towards
overseas study allowed tens of thousands of Chinese stu-
dents and scholars to go abroad for education and training.
However, only an estimated 25% of these students return to
China after their training [24]. In response, the Chinese
government has put in place an ambitious suite of pro-
grams and incentives to recruit back highly-trained Chinese
professionals and academics from abroad, with mixed
results [24]. For instance, Simon and Cao find that these
incentives have thus far failed to recruit the most-highly
trained and accomplished groups [24]. What is also uncer-
tain is whether those who do return will be sufficiently sup-
ported to stay for the long term, and if the skewed
compensation scheme in favor of returnees can be main-
tained without adversely affecting overall employee morale.
What is clear is that China’s ambitious R&D infrastructure-
building programs, as part of its overall goal to build an in-
novative and globally competitive bioeconomy, is likely to
create ongoing demands for specialized skills in various
areas. It remains to be seen whether current initiatives will
be sufficient to meet this demand.
Access to R&D infrastructure
As many companies in the emerging economies have
ventured into innovative activities only in recent years,their in-house R&D capabilities and infrastructure are
often limited. A common strategy to obtain required
services is to partner with researchers within univer-
sities and research institutes. This strategy is helpful to
a degree but a number of factors detract from its ef-
fectiveness. These include the historical lack of an
entrepreneurial culture within universities and the
traditional isolation of the public and private sectors
in these countries. Although governments have made
some efforts to bridge the divide between public and
private sectors – often through funding of collabora-
tive projects – in most cases there is little indication
that these efforts have made a significant impact. An
exception to this may be China, where the involve-
ment of government in many state-owned enterprises
(SOEs) is thought to make interactions with univer-
sities and research institutes easier for these firms. In
addition, China has embarked on an ambitious infrastruc-
ture-building exercise through its Hi-tech Parks Initiative.
In the span of less than 20 years, the country has built
54 high-tech parks, an estimated 20 of which have a
life sciences component. The largest of these is the
Zhangjiang Hi-Tech Park in Shanghai. Initiated in 1992,
this park occupies an area of 25 square kilometers and is
already home to over 4,000 enterprises, with approxi-
mately 400 being life science companies, institutes and
service providers. Other major life science clusters include
Zhongguancun Life Science Park in Beijing, and bioBay
in Suzhou, which is a joint project between China and
Singapore. These parks offer a host of benefits and invari-
ably have one or more incubator facilities, which especially
cater to small and medium technology-based enterprises.
While India and Brazil have a few clusters, that are similar
in certain respects, the scale and speed of development in
China is breathtaking by comparison.
Regulatory issues
One of the most common challenges facing innovation-
inspired firms in the emerging economies relates to the
clarity and effective enforcement of regulations govern-
ing health products. Again, while the outcome often
manifests in delays in regulatory approval, the under-
lying causes often vary across nations. For instance,
while a fragmented regulatory regime in India has his-
torically posed serious challenges to the growth of the
innovative health biotech sector, lack of practical experi-
ence on the part of Brazilian and South African regula-
tors was thought to make product approval challenging
in these countries. Other challenges in Brazil and South
Africa were primarily related to delays in approval of
clinical trials, which was perceived to detract from a
major competitive advantage possessed by these coun-
tries. In recent years India has been in the process of
reforming its biotech regulatory system by trying to
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tional Biotechnology Regulatory Authority (NBRA).
Long in coming and motivated in part by the desire to
better regulate genetically modified crops, limitations on
NBRA’s scope of activities serve to maintain the ana-
chronistic separation of institutions that govern small-
versus large-molecule drugs. In this sense, India is
missing the opportunity to create a truly centralized
regulatory agency, which can oversee all heath products
and optimize resultant synergies. China’s regulatory re-
gime has also had significant setbacks in recent years
due to corruption scandals involving some high-ranking
officials at the country’s SFDA. However, the agency has
rebounded from these challenges and has recently made
progress in a number of areas. For example, in early
2009 the SFDA instituted its Green Channel initiative,
which is an expedited approval process, allowing regula-
tors to waive requirements for Chinese trials for innova-
tive new drugs, new combinations, and those targeted at
unmet medical needs in the country. Furthermore, it has
undertaken a variety of initiatives aimed at addressing
product quality issues in the country’s vast and complex
pharmaceutical sector.
Intellectual property protection
The theoretical rationale underlying patenting is that it
incentivizes innovation efforts by creating a temporary
monopoly. The TRIPS agreement was an attempt to ex-
pand the number of countries and product classes where
such markets could be established. Although evidence
on the impact of strong IP protection on innovation
efforts of firms in all sectors is mixed [25-31], the rela-
tionship has been much more firmly established in the
pharmaceutical sector [32], albeit not in all countries
[33]. This is, in part, due to the fact that once discovered
pharmaceutical products/molecules are relatively easy to
copy and reproduce [34]. While it is generally believed
that IP protection incentivizes greater investments into
innovative R&D activities, it is not the only driver of
R&D expenditures. Market demand [35,36], and en-
hanced market valuation [37] are among other factors
that tend to motivate firm-based R&D.
While biopharmaceutical firms in all four countries
are increasingly cognizant of the importance of patent-
ing, issues related to the efficiency of processing patent
applications and effective enforcement of property rights
continue to create uncertainty. In all of the countries
studied except South Africa, a new pharmaceutical prod-
uct patent regime was formally adopted between 1993
and 2005. While these countries are still adjusting to the
new IP regime, they also struggle to minimize the nega-
tive impacts it might have for both public health and do-
mestic industries. These attempts have resulted in
country-specific peculiarities in patent legislation thatserve to diminish associated incentives and have led to a
few high-profile court cases – particularly in Brazil and
India where patent rights have either been denied or not
enforced as expected. Among the most controversial ele-
ments built into patent legislation are provisions related
to compulsory-licensing and those that aim to curtail
the practice of ‘ever-greening’, which allows companies
to collect monopoly rents by patenting minor changes to
a given drug whose patent life is about to expire. For in-
stance, in September 2009, the Indian patent office
rejected an application by Gilead Biosciences (Foster
City, USA) for the anti-AIDS drug tenofovir, in part
based on arguments that the application lacked sufficient
inventiveness. Brazil had earlier declined patent rights
for the same product, declaring it of interest to public
health in that country. Under the new Indian patent act,
new uses for existing products are not patentable unless
they demonstrate improved efficacy [18]. It is not yet
clear how this will impact domestic companies, many of
which are mainly concerned with improving existing
technologies such as combination vaccines and new
drug-delivery systems. Concerns regarding China’s pa-
tent regime stem primarily from the nature of its decen-
tralized enforcement regime. Patent infringement cases
are generally handled by municipal courts at the jurisdic-
tion of the accused, introducing potential conflicts of
interest into the process [38]. Amendments to China’s
patent legislation, which took effect in October 2009, are
aimed at enhancing the quality of patents, improving en-
forcement and alignment of China’s approach with that
of other major markets.
Innovation financing
While private financing, especially from institutional
investors, has been improving in the emerging markets in
recent years, relatively few of these investors back com-
panies that undertake highly innovative projects. Venture
capital (VC) firms that have made investment in innova-
tive companies include BioVeda China Fund (Shanghai),
APIDC Ventureast Biotechnology Venture Fund (Hydera-
bad, India), DFJ-FIR Capital (Belo Horizonte, Brazil) and
BioVentures (Cape Town, South Africa). Limitations on
financial exits for investors are thought to be a key con-
tributor to the shortage of VC investments in innovative
companies. The BOVESPA-MAIS (São Paulo) branch of
the Brazilian stock exchange and China’s recently
launched Shenzhen Stock Exchange aim at improving the
investment environment for technology-based companies.
On rare occasions, they have listed in foreign stock
exchanges as a way to achieve a more favorable valuation.
Recent interest in company acquisition by multinational
corporations in China and India may provide yet another
avenue for investors to divest, and may eventually attract
more investors into the sector. Volatility of stock markets,
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sophisticated secondary markets are all detrimental to fi-
nancing of high-risk innovation projects. The role of debt
financing and the need to attract foreign capital in non-
debt forms are crucial in the context of emerging markets.
In the meantime, many companies in the emerging mar-
kets, particularly the small and medium enterprises, rely
considerably on governmental support to finance
innovation projects.
Role of the state in advancing innovation
Overall commitment to science and technology develop-
ment, as measured by national R&D expenditure, has
been growing in all four emerging markets studied.
China’s R&D expenditures as a portion of its gross do-
mestic product (GDP) was 1.44% in 2007, amounting to
approximately US$102 billion in purchasing power par-
ity (PPP) – a more than doubling from its US$39 billion
expenditure in 2002 [39]. While India and Brazil’s
expenditures remained fairly constant as a portion of
GDP (at 0.78% for India and 1% for Brazil), their real
R&D investments nearly doubled during the 2002–2007
period due to GDP growth – rising from approximately
USD 13 to 25 billion in India and US$13 to 20 billion in
Brazil in PPP [40,41]. South Africa doubled its R&D
expenditures between 1997 and 2005 when its overall
R&D expenditures were 0.9% of GDP, approximately
53% of which was contributed by the business sector
[42]. In contrast, businesses R&D expenditures as a per-
centage of national expenditures constituted 29.6% in
India, 44.7% in Brazil, and 70.4% in China in 2007 [43].
Among the countries studied, China has the largest
pool of public money dedicated to its science and tech-
nology programs. It administers much of these funds
through three key programs: the High-Tech Research
Development Program (known as the 863 Program), the
Torch Program, and the National Key Basic Research
Program (known as the 973 Program). The Torch Pro-
gram is perhaps of most direct significance to the indus-
try as the other two primarily focus on basic research.
This program has an array of initiatives designed to sup-
port development of new technology industries. Since its
inception in 1988, it has facilitated the building of 54
National High-tech Parks, which are designed to inte-
grate R&D, manufacturing and enterprise incubation.
The Torch program also administers a 7 billion RMB
(US$1.02 Billion) innovation fund (Innofund), which
funded 11,980 firms from 1999–2007, with approxi-
mately 20% of funds devoted to biotechnology. China’s
12th Five-year Plan (2011–15) had dedicated US$308 bil-
lion to science and technology development with bio-
technology as a priority sector for advancement.
India’s Department of Biotechnology (DBT) is the lead
government agency that promotes biotechnology andpharmaceutical innovation in the country. DBT targets
approximately one third of its annual budget – esti-
mated at approximately Rs. 900 Crores (~US$201 M) for
2008/9 – to promoting public-private collaborations.
Among its key programs supporting industrial R&D is
the Small Business Innovation Research Initiative
(SBIRI), which in 2009 provided funding for 48 projects
within enterprises. The DBT’s other key foci are in skill
development and regulatory reform. The overall contri-
bution from other agencies, particularly with respect to
support of R&D within enterprises has been more mod-
est thus far.
In Brazil, the Studies and Projects Funding (FINEP)
Program of the Ministry of Science and Technology is
the key program that supports enterprise R&D. Through
a series of initiatives, including sector-specific funds and
investments in venture capital funds, FINEP aims to ad-
vance innovation within the industrial sector. One of its
latest initiatives is the Prime Program (Primeira Empresa
Inovadora), which aims at supporting approximately
5,000 technology-based startup companies between
2009–2011. It offers R$120,000 (~US$68,000) in grants
to each enterprise over the first year, followed by
interest-free loans for qualifying applicant during the
subsequent year.
The 2001 National Biotechnology Strategy in South
Africa was the key policy instrument that highlighted
the need to capture the commercial opportunities
offered by biotechnology. The strategy led to the estab-
lishment of Biotechnology Regional Innovation Centers
(BRICS), the main government initiatives in biotech de-
velopment. The South African government had ear-
marked 450 million Rands ($58 million) from 2004–
2007 for related initiatives [12].
Overall, governments in China, India, Brazil and South
Africa have played a crucial catalytic role in spurring
health product innovation within the private sector – al-
beit on a limited scale. While all of the countries studied
have housed strong universities and research institutes
for decades, to kindle innovative activities within the pri-
vate sector has required more focused government pol-
icies. It is noteworthy that the mere adoption of a
product patent regime in pharmaceuticals by China in
1993 (even prior to its adoption of the TRIPS agreement
and its enforcement in 2001), by Brazil in 1997, and the
expectation of the pending TRIPS enforcement in India
in 2005 were not sufficient, on their own, to spur signifi-
cant entrepreneurial investment into the development of
novel health products. Rather, entrepreneurial commit-
ment to innovation, as a trend, became noticeable con-
comitant with increased government support for
innovation within the entrepreneurial sector. In our ex-
perience the majority of emerging market companies
that undertake innovation projects, with the objective to
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mental assistance. The more recent and targeted govern-
ment policies attempt to increase entrepreneurial
commitment to innovative R&D by direct subsidization
of these efforts and/or through indirect measures. The
latter mechanisms include building of shared R&D infra-
structure, particularly in China, enhancing entrepreneur-
ial access to public-sector R&D resources in Brazil,
support of technology-focused venture capital funds
most notably in China and Brazil, and the creation of
Biotechnology Regional Innovation Centers in South Af-
rica. It remains to be seen whether governmental efforts
in these nations will be of sufficient scale and duration
to help galvanize the private investments necessary for a
successful transition to innovative sectors.
Relatively high and fast-rising domestic consumption
is undoubtedly contributing to the biopharmaceutical
sector’s development in the key emerging markets stud-
ied. At the same time, how governments implement
cost-containment and central procurement measures
may have considerable implications for innovation
within the sector – particularly for diseases that pre-
dominantly affect local, and other developing world,
populations.
Integration into the global innovation system
Four key trends point to the globalization of health
innovation, with a growing integration of emerging market
firms, particularly evident in India and China. These
trends add to existing relationships between pharma-
ceutical MNCs and emerging market firms, which have,
until recent years, been largely limited to contract ma-
nufacturing and marketing. First, as discussed previ-
ously, there is an increasing number of co-development
partnerships between firms in China and India and their
foreign counterparts. Through these partnerships, com-
panies in emerging economies have developed capabil-
ities that have enabled independent basic research and
commercialization. Second, large multinational cor-
porations finance some innovation projects within
emerging market firms in return for future develop-
ment/marketing rights. These relationships rely on de-
velopment of IP generated and/or owned by the
emerging market partner. This practice has augmented
the capabilities of emerging-economy partners with cru-
cial relationships that subsequently enable independent
commercialization and marketing activities. Third, the
emergence of R&D services-based businesses that pro-
vide sophisticated and cost-effective research, develop-
ment, and manufacturing should further augment
innovative capabilities of the sectors as a whole at a time
when the independent innovative capacity of multi-
national companies may be waning. Fourth, another
emerging trend is the acquisition of domesticbiopharmaceutical firms by foreign entities and the
growing presence of the former in other nations. Exam-
ples of the first include recent acquisition of: India’s
Shantha Biotechnics (Hyderabad) and Brazil’s Medley
(São Paulo) by Sanofi Aventis (Paris, France), Piramal
Healthcare (Mumbai) by Abbot Laboratories (Abbott
Park, IL), India’s Ranbaxy by Takeda (Daiichi Sankyo,
Tokyo), South Africa’s Vision Biotech (Cape Town) by
Inverness Medical Innovations, Inc. (Waltham, MA), and
China’s Guangdong Techpool Bio-Pharma (Guangzhou)
by the Swiss drug maker Nycomed (Zurich, now part of
Osaka-based Takeda Pharmaceutical Co.). Select emer-
ging market firms have also ventured to expand their
global presence through acquisitions or setting up sub-
sidiaries. For instance, China’s CapitalBio Corporation
has subsidiaries in San Diego (USA) and Hong Kong,
Piramal Healthcare has a subsidiary in Canada (Torcan
Chemical Ltd., Aurora). The above trends, as well as do-
mestic industry consolidation serve to augments cap-
abilities and enhance specialization, which makes
indigenous enterprises more competitive globally.
Whether integration into the global system, on balance,
proves beneficial to the emerging markets, or other devel-
oping nations, remains an open question. The suggestion
here is merely that this phenomenon is indeed taking shape
and in doing so is creating new opportunities – as well as
new challenges – for emerging market entrepreneurs.
Conclusions
This study shows that while China, India, Brazil and
South Africa vary in certain respects, entrepreneurs in
each of these countries aspire to become innovative in
biopharmaceuticals, and have made inroads against this
objective. Regardless of geography, these entrepreneurs
are affected by similar forces and often respond in analo-
gous ways. There are important similarities in national
approaches to: enhancing innovative capabilities, break-
ing down innovation barriers, financing innovative ac-
tivities often through innovative business models,
collaborating with international firms, profiting from in-
tellectual property, and to facing global competition.
The commonalities highlight that biopharmaceutical
firms in the China, India, Brazil and South Africa are
influenced by forces emanating, in part, from industry
globalization. Consequently, their responses carry impli-
cations for the global industry as a whole.
Our research shows that the trajectories of companies
in the developed and emerging economies are becoming
increasingly intertwined. Few of the firms we studied
planned on developing novel therapeutics for global con-
sumption fully on their own because they do not have
the necessary technical and financial resources and can-
not tolerate the associated investment risks. As a result,
promising leads in development within the emerging
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of major global players, or be developed through collab-
orative arrangements with other firms. Enhanced in-
novative capabilities in the emerging markets, the
associated cost arbitrage, and improved IP protection
regimes are increasingly facilitating outsourcing of R&D
activities from pharmaceutical MNCs to emerging mar-
ket firms. Yet many of the companies we studied also
aspired to global competitiveness within an element of
the value chain. The new pattern that seems to be emer-
ging is a globally disintegrated drug development value
chain with greater participation of the emerging markets
at different stages of activity. This is not to suggest that
this evolution will reduce diversity in business models.
Indeed the opposite is likely to be true as companies
carve out specific niches within an expansive, global
value-chain.
In summary, the ultimate outcome of each country’s
collective activity is likely to be shaped as much by global
factors as local conditions. It is exceedingly important to
realize that success in biopharmaceutical innovation is
about the hard work of adapting scientifically, nationally
and globally all at the same time. The implication is that
countries that can best understand this complexity and
situate their own strengths vis-à-vis the broader global
value chain will be most likely to achieve sustainable com-
petitive advantage. It is also possible that the globalization
of biopharmaceutical innovation will have deleterious
effects on domestic industries in the emerging markets,
and on access to health technologies in the developing
world. Failure to sufficiently adapt to new realities could,
for instance, lock emerging market firms into low-value
segments of the innovation value chain for years to come,
and/or limit their growth prospects by preventing access
to new technologies. These areas deserve further study
and continued vigilance to minimize adverse impacts on
emerging market industries and pharmaceutical access.
Notwithstanding above observations, recent develop-
ments in the emerging markets have the potential to
change the global drug development model itself, with a
promise to making it more productive and accessible. It
offers the possibility for more cost-effective innovations
and significant impacts on health systems everywhere.
Technological upgrading within many of the existing
pharmaceutical manufacturers in the emerging markets
is leading to a more competitive global pharmaceutical
generics market – leading to lower drug prices. At the
same time, we are witnessing the birth of a highly inte-
grated global industry when it comes to innovation –
promising greater therapeutic choice and lower drug de-
velopment costs. In this respect, emerging markets with
greater economies of scale, in terms of domestic market
size, and the scope of capabilities built over time appear
to be in an advantageous position. The implication isthat smaller countries such as South Africa with more
limited biopharmaceutical purchasing power and skill-
base to build on appear to be at a disadvantage vis-à-vis
China and India. Similarly, historical dominance of the
state sector and a host of other institutional factors con-
tribute to dampening Brazil’s potential when it comes to
health technology innovation. On the whole however,
greater involvement of the entrepreneurial sectors in the
emerging markets in health innovation holds consider-
able promise for patients everywhere.
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